Scleroderma and Fibrosis Research Enhancement Act of 2015
Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.
Scleroderma and Fibrosis Research Enhancement Act of 2015
This bill requires the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) to establish the National Commission on Scleroderma and Fibrosis Research. (Scleroderma and fibrosis are connective tissue conditions that cause hardening or scarring of skin and organs.)
The commission must develop a long-term, comprehensive plan for scleroderma and fibrosis research. The plan must: (1) prioritize research that has cross-cutting value and requires coordination across NIH, and (2) include specific steps for implementation of the research.
The commission must establish working groups to make research recommendations for the various organs and systems impacted by fibrotic illness.
The commission must be terminated not later than two years after establishment.
The NIAMS must create the Scleroderma and Fibrosis Working Group to oversee and assist with implementation of the long-term plan.Referred to the Subcommittee on Health.
- Introduced in House Formatted Text PDF Formatted XML
Cite this page
U.S. Congress. (2026). H.R. 3666: Scleroderma and Fibrosis Research Enhancement Act of 2015. 114th Congress. Open America. https://openamerica.io/bill/114-HR-3666/
"H.R. 3666: Scleroderma and Fibrosis Research Enhancement Act of 2015." 114th Congress, 2026, Open America, https://openamerica.io/bill/114-HR-3666/.
H.R. 3666, 114th Cong. (2026), https://openamerica.io/bill/114-HR-3666/.
[H.R. 3666: Scleroderma and Fibrosis Research Enhancement Act of 2015](https://openamerica.io/bill/114-HR-3666/)